At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,462 enrolled
Drug / intervention
bempedoic aciddrug
Likely dose
bempedoic acid 180 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Open-Label Extension (OLE) Study To Assess The Long-Term Safety and Efficacy of Bempedoic Acid (ETC-1002) 180 MG
In Brief
A Phase 3 clinical trial evaluating bempedoic acid for Hypercholesterolemia and Atherosclerotic Cardiovascular Disease. Completed, enrolled 1,462 participants across 3 sites.
Detailed Summary
The purpose of this study is to see if bempedoic acid (ETC-1002) is safe and well-tolerated in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartFeb 2017
First PostedMar 2017
Primary CompletionNov 2019
TodayJul 2026
First PostedMar 1, 2017
Enrollment StartFeb 3, 2017
Primary CompletionNov 5, 2019
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 9.3 years ago
Interventions
bempedoic aciddrug
bempedoic acid 180 mg tablets taken orally, once per day.